FIG 7.

Basal IFNK is modestly affected by JAK/STAT signaling. (a) HFK, HPV16⁺, and E5 Stop cells were treated with IFN-β with or without 10 μM ruxolitinib (Rux) for 24 h. IFNK transcript levels were measured using RT-qPCR. (b) The efficacy of JAK1-targeting siRNA (siJAK1) versus nontargeting control (NTC) was tested in HPV16-containing cells by Western blotting. (c) The levels of IFN-κ transcripts in cells transfected with siJAK1 were measured by RT-qPCR. NS, not significant; *, P < 0.05; ***, P < 0.001. The error bars indicate standard error of the mean.